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Abstract: 
Expansion of a polyglutamine tract in Huntingtin (Htt) leads to the degeneration of medium 
spiny neurons in Huntington's disease (HD). Furthermore, the HTT gene has been functionally 
linked to iron (Fe) metabolism, and HD patients show alterations in brain and peripheral Fe 
homeostasis. Recently, we discovered that expression of mutant HTT is associated with impaired 
manganese (Mn) uptake following overexposure in a striatal neuronal cell line and mouse model 
of HD. Here we test the hypothesis that the transferrin receptor (TfR)–mediated Fe uptake 
pathway is responsible for the HD-associated defects in Mn uptake. Western blot analysis 
showed that TfR levels are reduced in the mutant STHdhQ111/Q111 striatal cell line, whereas 
levels of the Fe and Mn transporter, divalent metal transporter 1 (DMT1), are unchanged. To 
stress the Fe transport system, we exposed mutant and wild-type cells to elevated Fe(III), which 
revealed a subtle impairment in net Fe uptake only at the highest Fe exposures. In contrast, the 
HD mutant line exhibited substantial deficits in net Mn uptake, even under basal conditions. 
Finally, to functionally evaluate a role for Fe transporters in the Mn uptake deficit, we examined 
Mn toxicity in the presence of saturating Fe(III) levels. Although Fe(III) exposure decreased Mn 
neurotoxicity, it did so equally for wild-type and mutant cells. Therefore, although Fe 
transporters contribute to Mn uptake and toxicity in the striatal cell lines, functional alterations in 
this pathway are insufficient to explain the strong Mn resistance phenotype of this HD cell 
model. 
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Article: 
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder predominantly 
afflicting the corpus striatum. Expansion of a glutamine encoding CAG triplet repeat in the 
Huntingtin (HTT) gene causes HD (Walker, 2007). The medium spiny neurons of the corpus 
striatum are selectively lost during progression of HD. The pathophysiological basis of this 
selective pathology has not been fully elucidated. However, experimental evidence supports a 
number of underlying mechanisms including excitotoxicity and altered calcium signaling, 
mitochondrial dysfunction, oxidative stress, protein aggregation, loss of brain derived 
neurotrophic factor support, and others (Damiano et al., 2010; Graham et al., 2006, 2009; Heng 
et al., 2009; Roze et al., 2008; Strand et al., 2007; Zhang et al., 2008; Zuccato et al., 2001, 2005). 
 
Metals have well-defined physiological functions within the brain, yet overexposures cause 
neurodegeneration and/or neuronal dysfunction (Bossy-Wetzel et al., 2004; Brown et al., 2005; 
Coppede et al., 2006). Additionally, many neurodegenerative disorders have been associated 
with altered metal homeostasis, emphasizing the importance of maintaining optimal metal levels 
for normal brain function. Finally, analysis of metal neurotoxicity has revealed similarities in the 
pathophysiological mechanisms of HD and other neurodegenerative disorders (Aschner et al., 
2007; Fox et al., 2007; Molina-Holgado et al., 2007; Wright and Baccarelli, 2007). Both protein 
aggregation and oxidative stress, for example, have been implicated in the toxicity associated 
with HD and metal overexposure (Choi et al., 2007; Firdaus et al., 2006; Milatovic et al., 2009). 
Recognizing these similarities between HD and the toxicity of various metals, we performed a 
disease-toxicant interaction screen in a striatal neuronal cell line model of HD (Williams et al., 
2010). This screen revealed a neuroprotective interaction between manganese (Mn) exposure and 
HD in which a striatal cell model expressing an expanded CAG repeat HTT allele showed 
decreased net Mn uptake following Mn exposure relative to wild-type cells. We also observed 
reduced net Mn uptake specifically into the striatum following systemic Mn exposure of a mouse 
model of HD (Williams et al., 2010). Importantly, the screen revealed that the phenotype is 
specific to Mn and does not occur with other metals known to induce protein aggregation or 
oxidative stress (e.g., Fe, Cu, and Zn). The mechanisms by which Mn exerts its cytotoxicity is 
likely similar in the presence of mutant HTT as exposure conditions yielding similar increases in 
cellular Mn burden in wild-type and mutant HTT cells exhibit similar cell death (Williams et al., 
2010). With these data uncovering alterations in cellular Mn levels upon exposure, we focused 
on the pathways that contribute to cellular Mn transport. 
 
Iron (Fe) and Mn transport and homeostasis are tightly linked. The major cellular Fe uptake 
pathway, the transferrin receptor (TfR)–mediated Fe uptake system, has been shown to mediate 
the uptake of Mn in the 3+ valence but has higher affinity for Fe(III) (Malecki et al., 1999). Not 
only can trivalent Mn be transported by the TfR but changes in Fe homeostasis can alter Mn 
homeostasis (Aschner and Gannon, 1994; Erikson et al., 2004; Fitsanakis et al., 2008; Garcia et 
al., 2006, 2007; Keefer et al., 1970). DMT1 (also known as NRAMP2), which transports Fe(II) 
and Mn(II), is regulated by cellular Fe status (Fleming et al., 1998; Gunshin et al., 2001; Lee et 
al., 1998). Additionally, DMT1 plays a critical role in TfR-mediated Fe uptake, by mediating the 
release of Fe(II) from endocytic compartments (Fleming et al., 1998). Finally, the Fe exporter, 
ferroportin, has recently been shown to also contribute to Mn export (Yin et al., 2010). Evidence 
of coregulation in vivo and in vitro was reported in studies showing that both deficiency and 
repletion of either Fe or Mn is associated with changes in transport and homeostasis of the other 
metal (Erikson and Aschner, 2006; Erikson et al., 2002; Fitsanakis et al., 2008; Garcia et al., 
2006, 2007; Zheng and Zhao, 2001). 
 
A previous report utilizing a striatal neuronal cell line model of HD (STHdhQ111/Q111) found 
alterations in Fe signaling and increased expression of the TfR protein compared with a wild-
type cells (STHdhQ7/Q7) (Trettel et al., 2000). Also, HD patients display elevated levels of Fe 
and copper (Cu) in the corpus striatum in both postmortem and functional magnetic resonance 
imaging studies (Bartzokis et al., 1999; Dexter et al., 1991; Fox et al., 2007). HTT, in partnership 
with two of its interacting protein, has also been shown to function in magnesium transport 
(Goytain et al., 2008). Expression of HTT is elevated in response to increasing Fe levels 
(Hilditch-Maguire et al., 2000). Additionally, in zebrafish, the embryonic lethality due to Htt 
inactivation has been attributed to a failure of appropriate utilization of Fe stores (Lumsden et al., 
2007). Perhaps, most importantly, human mutations in a key Fe storage protein (L-ferritin) leads 
to neuroferritinopathy, a neurodegenerative condition with clinical similarities to HD (Curtis et 
al., 2001). Therefore, given our observations of decreased Mn uptake in both cellular and mouse 
models of HD and known functional links between Fe and Mn transport, we hypothesized that 
alterations in Fe homeostasis because of polyglutamine-expanded mutant HTT may underlie the 
decreased sensitivity to Mn toxicity and altered Mn transport. The objective of this study was to 
evaluate the contribution of alterations in Fe transport to the defect in Mn transport in the 
STHdhQ111/Q111 HD striatal cell model. 
 
MATERIALS AND METHODS 
 
Chemicals, reagents, and cell culture supplies. 
Cell culture media and supplements were obtained from Mediatech (Manassas, VA) unless 
indicated. Cell lines were grown in Dulbecco's modified Eagle's medium with 10% fetal bovine 
serum (Atlanta Biologicals, Lawrenceville, GA, and Sigma, St Louis, MO), L-glutamine, 400 
μg/ml G418, and Penicillin-Streptomycin. Mn(II) chloride was from Alfa Aesar (Ward Hill, 
MA). Fe(III) chloride was from Sigma. Buffers and solutions for assays: 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) salt (VWR, West Chester, PA), Sorenson's buffer 
(0.1M glycine, 0.1M NaCl2, pH 10.5), and DMSO (Sigma). 
 
Cell culture and survival assays. 
The clonal striatal cell lines—both mutant STHdhQ111/Q111 and wild-type STHdhQ7/Q7—
were a generous gift from Marcy MacDonald, PhD (Massachusetts General Hospital, MA), and 
grown at 33°C (Trettel et al., 2000). Culture and assays were performed as previously described 
(Williams et al., 2010). In brief, STHdhQ111/Q111 and wild-type STHdhQ7/Q7 cells were 
plated at equal density the evening before treatment. Metals were added to the culture media the 
next morning, and the cells were exposed for 3 or 30 h. Cell viability was assessed in 24-well 
culture plates with the MTT assay according to established protocols (Ehrich and Sharova, 
2000). Briefly, culture media was removed, and 500 μl of 0.5% MTT salt in minimal essential 
medium (MEM) (Invitrogen, Carlsbad, CA) containing FBS and Penicillin-Streptomycin was 
added to each well of the plate for 4 h. Next, the MEM was removed, and 200 μl of Sorenson's 
buffer diluted 1:8 in DMSO was added to the empty wells to dissolve the precipitate. The plates 
were returned to the incubator until all the MTT salt precipitate could no longer be visualized 
under a microscope. Samples were placed in a 96-well plate, and the absorbance was read at 
570–590 nm. Cell survival data were normalized by genotype to the vehicle-only exposed 
control included in each independent sample set. The concentrations of Mn and Fe were based 
upon previously reported cell survival curves (Williams et al., 2010). In brief, we reported the 
maximal difference in survival and cellular response to Mn exposure between the two STHdh 
cell lines was at 40μM Mn (∼50% difference in survival between wild-type and mutant cells). 
Furthermore, the 100μM Mn exposure was used because both cell lines exhibited clear Mn 
cytotoxicity at this concentration. It is also important to note that the amount of cell death in the 
mutant STHdh line exposed to 100μM Mn for ∼30 h approximates the levels of cytotoxicity in 
the wild-type line at 40μM Mn. Additionally, under these exposure conditions, the amount of Mn 
accumulated within the cells is equal. Animals exposed to Mn can accumulate the metal in the 
stratum to levels as high as 70μM being reported (Aschner et al., 2005). The 600μM Fe(III) 
exposure was chosen because as the maximal exposure as it showed minimal cytotoxicity in both 
the wild-type and mutant STHdh cells. 
 
Antibodies. 
Primary antibodies used include: TfR (Invitrogen), DMT1 (+iron-responsive element (+IRE) and 
−IRE forms) (NRAMP24-S; ADI, San Antonio, TX), and actin (Developmental Studies 
Hybridoma Bank, Iowa City, IA). Appropriate peroxidase-conjugated secondary antibodies from 
Jackson Immunoresearch Laboratories (West Grove, PA) were used accordingly: IgG mouse, 
IgG rabbit, and IgM mouse. 
 
Western blot. 
Equal numbers of wild-type and mutant STHdh cells were plated onto 10-cm2 plates, treated 
with Mn(II) chloride for 3 or 30 h, and harvested by trypsinization. The cell pellets were lysed in 
RIPA buffer (50mM Tris, 150mM NaCl2, 0.1% SDS, 1.0% Nonidet 40, 12mM deoxycholic 
acid, 1× protease inhibitor cocktail [Sigma], and 1× phosphatase inhibitor cocktails I and II 
[Sigma]) and loaded by equal cell number or equal protein for SDS-PAGE. Western blots were 
visualized with Thermo Scientific Pierce Supersignal West Dura Extended Duration 
Chemiluminescent Substrate (Waltham, MA) on an Ultralum Omega 12iC (Claremont, CA). 
Measurements of integrated density of protein bands were performed using ImageJ (NIH), with 
background correction calculated using a signal ratio error model, as described (Kreutz et al., 
2007). Calculations of relative signal were normalized to untreated wild-type or mutant sample 
for each set, as indicated. 
 
Graphite furnace atomic absorption spectroscopy. 
Total Fe and Mn concentrations were measured with graphite furnace atomic absorption 
spectroscopy (GFAAS) (Varian Inc., AA240, Palo Alto, CA). STHdh cells grown in 10-cm2 
plate were cultured and treated as described above for cell viability assays, harvested by 
trypsinization, total cell number was then counted by hemacytometer, the cell pellet was washed 
multiple times in PBS, and finally flash-frozen until analysis. To increase sensitivity for 
determination of basal Mn levels, cells from two 10-cm2 plates were combined before GFAAS 
analysis. For analysis, cell pellets were thawed and digested in 200-μl ultrapure nitric acid for 24 
h in a sandbath (60°C). Mn and Fe contents were determined by the following protocol: A 20-μl 
aliquot of the digested sample was brought to 1 ml total volume with 2% nitric acid for analysis. 
Bovine liver (NBS Standard Reference Material, USDC, Washington, DC) (10 μg Mn/g; 184 μg 
Fe/g) was digested in ultrapure nitric acid and used as an internal standard for analysis (final 
concentration 5 μg Mn/l; 92 μg Fe/l) as published previously (Anderson et al., 2009). Because of 
the small size of the cell pellets and genotype-specific differences in protein content, cellular Mn 
and Fe levels were calculated by normalizing to cell number for each sample (i.e., fmol 
metal/100 cells). To enable comparisons with other published values, we also report estimated 
metal content values for some of our measures expressed in calculated units of nmol Mn per mg 
protein. These values were calculated post hoc by measuring total cellular protein levels in wild-
type (0.207 mg protein/1 × 106 cells) and mutant cell lines (0.162 mg protein/1 × 106 cells) 
using the Bio-Rad DC protein assay (Bio-Rad, Hercules, CA) and hemacytometer counts. The 
change in net metal uptake above basal levels was calculated by subtracting the mean total 
cellular metal content (fmol metal/100 cells) under basal cell culture conditions by the mean total 
cellular metal content (fmol metal/100 cells) following a 30-h exposure. 
 
Statistical analysis. 
Univariate and repeated-measures ANOVA tests were performed using SPSS 18 software (IBM, 
Inc., Chicago, IL). Post hoc analysis and pairwise comparisons were done using Microsoft Excel 
(Microsoft, Redmond, WA) by Student's t-tests (two tailed) or testing for nonoverlap of the 95% 
confidence interval for normalized ratios; error bars are expressed as SEM. SDs for the change in 
net metal uptake above basal levels were calculated by appropriate propagation of uncertainty 
calculations for subtraction of sample means, with significant differences between wild-type and 
mutant cells evaluated by nonoverlap of the 95% confidence interval. 
 
RESULTS 
Decreased Levels of TfR and Mn Responsiveness in Mutant STHdh Cells 
 
To begin our investigation, we examined the levels of TfR between wild-type and mutant STHdh 
cell lines exposed for 3 h to varying concentrations on Mn. We used samples previously 
examined for AKT activation (Williams et al., 2010), which showed a selective deficit in Mn-
dependent activation in the mutant STHdhQ111/Q111 versus wild-type STHdhQ7/Q7 cells. 
Western blot analysis of these samples revealed a modest ∼20% decrease in TfR levels in mutant 
STHdhQ111/Q111 cells irrespective of exposure (Fig. 1). ANOVA found a significant effect of 
genotype (p = 0.001) but no effect of treatment nor a genotype-by-treatment interaction. The 
levels of TfR and other essential components of the Fe signaling pathway are altered in response 
to Mn intoxication (Kwik-Uribe and Smith, 2006; Kwik-Uribe et al., 2003; Li et al., 2005; Lu et 
al., 2005; Wang et al., 2008) as well as by mutant alleles of HTT (Hilditch-Maguire et al., 2000; 
Simmons et al., 2007; Trettel et al., 2000). To test the hypothesis that a 3-h Mn exposure is 
insufficient to observe an alteration in total TfR levels, we examined a 30-h exposure of cells to 
40μM Mn(II) chloride and measured protein levels. This exposure was selected based on our 
previous work demonstrating a substantial difference in Mn toxicity and Mn uptake between 
wild-type and mutant cells at this duration and concentration, yet low enough toxicity in the 
mutant as to enable sufficient survival for quantification of protein levels (Williams et al., 2010). 
Western blot analysis confirmed decreased TfR levels in the mutant line and revealed an increase 
in total TfR levels in Mn-exposed cells (Fig. 2). ANOVA found a significant effect of genotype 
(p < 0.001) as well as Mn treatment (p = 0.003) on TfR levels, with a trend for a genotype-by-
treatment interaction (p = 0.18). Post hoc pairwise comparisons demonstrated a significant 
decrease in TfR levels between wild-type and mutant cells under both basal and Mn exposure 
conditions (p < 0.05). In addition, with the 30-h exposure to 40μM Mn, we observed an increase 
in cellular levels of TfR in the wild-type cell line (p < 0.05). However, the change was not 
significant in the mutant STHdhQ111/Q111 cell line after exposure to Mn, consistent with a 
decreased responsiveness of the mutant STHdhQ111/Q111 cell line to Mn exposure. 
Figures 1 & 2 are omitted from this formatted document.  
 
DMT1 Levels Are Unchanged in HD Mutant Cell Line 
Bioavailability of endocytosed transferrin-bound Fe is mediated in part by the proton-coupled 
metal transporter, divalent metal transporter 1 (DMT1). To determine if changes in TfR levels 
correspond to alterations in cellular DMT1 levels, we used Western blot analyses to measure 
total protein levels in vehicle and 30-h 40μM Mn-exposed cells (Fig. 3). ANOVA found no 
significant difference in DMT1 levels as a measure of genotype, Mn exposure, or two-way 
interaction for treatment × genotype. There was a slight trend (p = 0.098) toward increased 
DMT1 levels in mutant cells overall—but this was not statistically significant. 
 
Figure 3 is omitted from this formatted document. 
Net Fe Accumulation after Fe Exposure Is Moderately Reduced in HD Mutant Cells 
 
Our previously published data examining total Fe accumulation following Mn exposure showed 
a statistical trend (p = 0.118) for a two-way interaction between Mn exposure and genotype 
(Williams et al., 2010), in which an increase in Fe levels with Mn exposure was seen only in 
wild-type cells. Given the reduced expression of TfR in the mutant striatal cells (Fig. 1), we 
tested the hypothesis that mutant STHdhQ111/Q111 cells would show reduced Fe accumulation 
following Fe exposure versus wild-type cells. We compared total cellular Fe levels measured by 
GFAAS between wild-type and mutant cells under either basal conditions or exposure to 100 or 
600μM Fe(III) chloride for 30 h (Fig. 4A). Fe levels were chosen to enable a comparable 
concentration with our 100μM Mn exposures and a high concentration (600μM Fe(III)) to stress 
the Fe pathway maximally. Mutant STHdhQ111/Q111 cells showed a slight decrease (∼30%) in 
Fe accumulation versus wild-type cells under 100μM Fe exposures, but this difference was not 
significant (p = 0.151). However at 600μM Fe exposure, a significant difference (p = 0.038) was 
seen in which mutant STHdhQ111/Q111 cells accumulated approximately 40% less Fe than 
wild-type cells (Fig. 4A; 600μM). 
 
FIG. 4. 
Net Fe uptake is reduced in the HD striatal cells. (A) Measurement of total intracellular Fe levels 
in STHdhQ7/Q7 or STHdhQ111/Q111striatal cell lines (as indicated) after application of the indicated 
concentrations of Fe(II) chloride for 30 h (n = 3 to 5). Mean values (±SEM) are plotted on a 
linear scale. (B) Comparisons of net Fe uptake versus net Mn uptake above basal levels (vehicle 
control) in STHdhQ7/Q7 (blue) versus STHdhQ111/Q111 (red) cells following a 30-h exposure to 
these metals. Calculations are derived from Fe data in (Fig. 4A) and previously published Mn 
data (Williams et al., 2010). Data expressed as the absolute difference (±SEM) between metal-
exposed and vehicle-exposed cells (n = 3–5), plotted on log10 scale. “*” Indicates a significant 
difference in net metal uptake (p < 0.05, using 95% confidence intervals) between wild-type and 
mutant cells. 
 
Magnitude of Mn Uptake Deficit in HD Mutant Cells Greatly Exceeds Fe Uptake Deficit 
 
To explore the magnitude of the differences between net Mn versus net Fe accumulation in the 
HD cell model, we compared the degree of accumulation for each metal above basal levels 
between wild-type and mutant cells after exposure to low and high levels of the metal (Fig. 4B). 
Basal cellular Fe levels are approximately 10-fold higher than basal cellular Mn levels in wild-
type cells (Fig. 5). To adjust for this difference, we examined the differences in fold-change of 
cellular metal content between Fe and Mn following exposure (i.e., the ratio of Fe levels 
following Fe exposure over basal Fe levels versus the ratio of Mn levels following Mn exposure 
over basal Mn levels). We found that the proportional rise in metal content in wild-type cells is 
similar between 100μM Fe (5.6-fold ± 2.3 SEM) and 40μM Mn (5.8-fold ± 1.2 SEM) exposures. 
Likewise the proportional rise was similar between 600μM Fe (68-fold ± 25 SEM) and 100μM 
Mn (90-fold ± 17 SEM) exposures. Considering this in another way, we examined the absolute 
rise in metal above basal cellular levels (i.e., the difference between metal levels postexposure 
and basal levels). We found that the absolute increase in cellular Fe levels for 100μM Fe 
exposure (+132 fmol Fe per 100 cells) was between the range of absolute net Mn uptake for the 
40μM Mn exposure (+32 fmol Mn per 100 cells) and the 100μM Mn exposure (+587 fmol Mn 
per 100 cells) in wild-type cells (Fig. 4B). Thus, the Fe and Mn exposures examined led to 
comparable changes in cellular metal levels in wild-type cells. 
 
FIG. 5. 
Basal Mn deficiency in HD striatal cells. Measurement of total intracellular Fe and Mn by 
GFAAS of cells collected from two 10-cm2plates per sample of STHdhQ7/Q7 or 
STHdhQ111/Q111 cells (as indicated). Cells grown under standard culture conditions without 
supplemented Mn(II) or Fe(III). The mean total metal levels (±SEM) are plotted as indicated. “*” 
Indicates a significant difference in measured metal levels (p < 0.05, t-test) between wild-type 
and mutant cells. 
Given comparable metal transport activity between these Fe and Mn exposures, we compared net 
metal uptake between wild-type and mutant HD cells. We found a subtle decrease (<40%), 
which did not reach statistical significance, in net Fe uptake in mutant HD cells relative to wild 
type for both Fe exposures (Fig. 4B). In contrast, we found a substantial and significant decrease 
(>90%) in net Mn uptake in mutant HD cells relative to wild type for both the 40 and 100μM Mn 
exposures (Fig. 4B). 
Mutant HD Striatal Cells Exhibit a Basal Mn Deficiency 
The analysis described above revealed that differences in TfR levels and Fe accumulation upon 
exposure do not correspond with a significant decrease in total cellular Fe content under basal 
culture conditions (Fig. 4A). Given the striking deficit in net Mn uptake, we sought to better 
evaluate the basal levels of Mn in the mutant STHdhQ111/Q111 cells because extracted Mn levels 
were near the detection limit of the GFAAS in our previously published study (Williams et al., 
2010). To increase the accuracy in measurement of basal Mn levels, we pooled plates of wild-
type or mutant cells grown under basal culture conditions before GFAAS analysis. GFAAS 
measurements of total Fe and Mn levels confirmed no difference in basal Fe levels but revealed a 
substantial (∼4-fold) and significant (p = 0.004) deficiency in basal Mn levels in the mutant 
STHdhQ111/Q111 cells (Fig. 5). Basal Mn levels in the wild-type cells were 3.92 fmol per 100 cells 
(∼0.189 nmol Mn per mg protein), whereas in the mutant cells basal levels were lower at 1.12 
fmol per 100 cells (∼0.069 nmol Mn per mg protein). 
Saturating Levels of Fe Block Mn Toxicity Independent of HD Genotype 
To address more directly the role of Fe transport and its potential contribution to the HTT-Mn 
gene-environment interaction, we examined the toxicity of Mn in the presence of saturating 
levels of Fe(III), 600μM (Fig. 6). At 600μM Fe(III), cell survival was significantly decreased in a 
dose-dependent manner as determined from previously published data (Williams et al., 2010). 
We reasoned that at high levels of Fe(III), the TfR pathway would be saturated, thereby limiting 
the transport of other metals through this pathway. Thus, we expected that high levels of Fe(III) 
would decrease the toxicity of Mn(II) taken up by this Fe-saturable transport system but would 
have minimal influence on Mn toxicity driven by uptake systems that are independent of Fe. 
Furthermore, if changes in the activity of Fe transport pathways substantially contributed to the 
changes in net Mn uptake in the HD cell model, then we would expect saturating levels of Fe(III) 
to suppress the HTT-Mn gene-environment interaction. We report that saturating amounts of 
Fe(III) diminish Mn toxicity in both cell lines (Fig. 6A). A three-factor repeated-measures 
ANOVA (Fig. 6B) found a significant effect of genotype (p = 0.035), Mn exposure (p < 0.001), 
and a two-way interaction between genotype and Mn exposure (p = 0.017), recapitulating the 
gene-environment interaction we have previously reported (Williams et al., 2010). The ANOVA 
revealed no significant effect of Fe exposure nor a significant two-way interaction for Fe 
exposure and genotype, indicating no differential sensitivity to Fe toxicity between the two cell 
lines, also as previously reported (Williams et al., 2010). However, a significant two-way 
interaction between Fe-exposure and Mn-exposure was observed (p = 0.004), demonstrating that 
Fe exposure reduces Mn toxicity. Importantly, the ANOVA also found no significant three-way 
interaction of genotype by Mn exposure by Fe exposure (Fig. 6B). This indicates that although 
Fe reduced Mn toxicity, it did so equally for wild-type and mutant cells. Controlling for Fe 
toxicity, the difference in percent cell survival between wild-type and mutant cells following a 
30-h 100μM Mn(II) exposure was similar and independent of coexposure to 600μM Fe(III) (Fig. 
6C). 
Figure 6 has been omitted from this formatted document. 
DISCUSSION 
We tested the hypothesis that alterations in Fe transport contribute to a defect in Mn transport 
that confers resistance to Mn toxicity in a striatal cell line model of HD (Trettel et al., 2000; 
Williams et al., 2010). Our data demonstrate alterations in the TfR-mediated Fe transport 
pathway and differences in cellular Fe uptake with overexposure in mutant STHdhQ111/Q111 cells 
compared with wild type (Figs. 1, 2, and 4A). However, this deficit in Fe uptake does not 
translate into a significant difference in net Fe uptake above basal levels between wild-type and 
mutant cells exposed to high levels of Fe (Fig. 4B). Thus, it is likely that compensatory changes 
are occurring to maintain Fe homeostasis. In contrast, the rise in net Mn levels above basal levels 
in mutant STHdhQ111/Q111 cells treated with Mn is substantially less than what occurs in wild-type 
cells. Furthermore, we find that saturating Fe(III) levels partially suppress Mn(II) toxicity, 
consistent with a contribution of cellular Fe transport systems in regulating Mn trafficking (Fig. 
6). 
Despite a role for Fe-transport systems in Mn uptake, we found that both mutant and wild-type 
cells are equally protected from Mn toxicity by high levels of Fe. The toxicity of Fe(III), Cu(II), 
Pb(II), Co(II), Zn(II), and Ni(II) were previously reported to be similar between wild-type and 
mutant cells (Williams et al., 2010). Also mutant STHdhQ111/Q111 cells are more sensitive to 
Cd(II) (Williams et al., 2010). Each of these metals are substrates for DMT1, some with higher 
affinities than Mn(II) (Gunshin et al., 1997). Thus, coupled with evidence reported here that total 
DMT1 levels are unchanged (Fig. 3), it is unlikely that DMT1 is responsible for the difference in 
Mn transport in the HD models. In addition to DMT1, the ZIP8 family of transporters, 
metal/bicarbonate ion symporters, have been shown to transport Fe and Mn (Girijashanker et al., 
2008; He et al., 2006;Liuzzi et al., 2006). But, again as Zn and Cd are also transported by this 
family of transporters, the ZIP8 family is unlikely to contribute to the Mn accumulation defect in 
our HD model. Altogether, these analyses strongly argue that defects in known Fe transport 
pathways are not sufficient to explain the HD-Mn disease-toxicant interaction. 
Alterations in Fe transport and Fe homeostasis have previously been reported in HD 
experimental models and patients (Bartzokis et al., 1999;Dexter et al., 1991; Fox et al., 
2007; Trettel et al., 2000). We find that total TfR levels are decreased in the mutant 
STHdhQ111/Q111 cells compared with wild-type STHdhQ7/Q7 cells (Figs. 1 and 2). Previous studies 
with early passage lines by Marcy MacDonald and colleagues reported increased TfR levels and 
increased transferrin uptake activity (Trettel et al., 2000). In contrast, the cells utilized in this 
study are of a later passage, and based on data here, the mutant cells seem to have reduced TfR 
levels, yet normal cellular Fe uptake relative to the wild-type cells. Indeed, despite reduced 
levels of TfR protein in the mutant cells, total Fe levels under basal culture conditions between 
wild-type and mutant cells are not significantly different (Figs. 4 and 5). Furthermore, time in 
culture (perhaps related to cell density) also appears to influence TfR levels—compare difference 
in TfR levels in the 3-h exposure condition (Fig. 1) with the 30-h exposure condition (Fig. 2). 
Thus, it is likely that the decreased TfR levels in the mutant cells is a reflection of regulatory 
actions by the cells to maintain cellular Fe homeostasis. 
We observe a significant increase in total TfR levels with the 30-h 40μM Mn exposure in wild-
type cells, but not mutant cells. Furthermore, this increase does not occur as early as 3 h after 
exposure, even at very high levels of Mn. Increased TfR levels following Mn exposure has been 
reported in both animal and cellular models (Garcia et al., 2006; Li et al., 2005; Zheng et al., 
1999). The failure to significantly elevate TfR levels in the mutant cells (Fig. 2) was concurrent 
with decreased Mn uptake (Fig. 4B). Thus, the regulatory mechanisms that link Mn exposure to 
elevated TfR levels are likely dependent on intracellular rather than extracellular Mn. 
We find that the STHdh striatal cell model of HD exhibits a substantial deficiency in total 
cellular Mn content under basal culture conditions (Fig. 5). This raises the possibility that the 
disease-causing allele of HTT may lead to a defect in neuronal Mn homeostasis. Thus, in 
addition to the reported alterations in Fe and Cu levels in HD (Bartzokis et al., 1999;Dexter et 
al., 1991), our observations suggest that Mn changes may also occur. Only one study that we are 
aware of has examined Mn levels in HD patient brains, reporting no significant alterations in 
brain Mn levels; however, this study examined only four HD striatal samples and therefore was 
statistically underpowered to detect small changes (Dexter et al., 1991). Our earlier study 
reported decreased Mn uptake after subcutaneous Mn exposure in the presymptomatic 
YAC128Q mouse model of HD, specifically in the striatum (Williams et al., 2010). However, 
we did not detect a deficiency in basal Mn levels. Future studies should evaluate whether 
examining specific cell types (e.g., neurons versus glia) or disease progression (e.g., older 
animals) may reveal a change in basal Mn levels. 
There are few reports on the phenotypes because of Mn deficiency in adult animals, but Mn is 
required for the proper function of many enzymes key to brain function (e.g., glutamine 
synthetase [GS], pyruvate carboxylase, superoxide dismutase 2 [SOD2], arginase, and 
serine/threonine protein phosphatase) (Applebury et al., 1970; Eid et al., 2008; Ensunsa et al., 
2004; Greger, 1999; Tholey et al., 1988a, 1988b;Wedler et al., 1994). Several of these Mn-
dependent enzymes have direct links to HD. For example, the activity of GS, which metabolizes 
glutamate, an excitatory neurotransmitter, to glutamine, is decreased in the corpus striatum of 
HD patients (Butterworth, 1986; Carter, 1981). However, other glial-specific activities are 
elevated, suggesting that GS activity is not lost because of general glial cell loss (Butterworth, 
1986). Importantly, expression of mutant htt in astrocytes and reductions in GS activity are both 
associated with increased excitotoxicity (Fernandes et al., 2007; Shinet al., 2005; Zeron et al., 
2001). Additionally, deficiencies in SOD2 have been shown to increase sensitivity to 3-
nitropropionic acid (3-NPA), a toxicant that has been used to model HD (Andreassen et al., 
2001; Beal et al., 1993). Of note, the mutant STHdhQ111/Q111 cells are hypersensitive to 3-NPA 
(Trettel et al., 2000; Williams et al., 2010). Finally, the Mn-dependent enzyme arginase regulates 
the final step of the urea cycle in liver; both HD patients and mouse models have deficiencies in 
the urea cycle (Chiang et al., 2007; Stoy et al., 2005). Thus, alteration in Mn homeostasis has the 
potential to influence a variety of enzymes whose activities have clear pathophysiological links 
to HD. 
In summary, expression of mutant HTT was found to alter Mn homeostasis in a mouse striatal 
cell model of HD. Saturating Fe exposure reduced Mn toxicity, indicating a clear link between 
Fe transport pathways and regulation of cellular Mn levels. However, altered Mn homeostasis 
was not explained by confirmed HD-associated defects in Fe transport pathways because Fe 
protected against Mn cytotoxicity equally in wild-type and mutant cells. Therefore, some other 
Mn uptake, storage, or efflux mechanisms must be altered in this HD model and account for the 
substantial deficit in net Mn uptake. Future studies will be needed to examine the cellular basis 
for the Mn transport defect and the potential role of HTT (direct or indirect) in regulating cellular 
Mn levels. Given the decreased striatal Mn uptake following Mn exposure in the YAC128Q HD 
mouse model we have previously reported (Williams et al., 2010), future studies will also need 
to examine the role of these Mn transport pathwaysin vivo. Interestingly, there is a precedent of 
pathophysiological interactions between metals such as Mn and proteins associated with 
neurodegenerative diseases (Choi et al., 2006, 2007, 2010; Gitler et al., 2009). Thus, changes in 
Mn homeostasis because of the disease-causing allele of HTT may potentially contribute to the 
selective degeneration of medium spiny neurons in the corpus striatum that occurs in HD. 
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